Filing Summary
Registrant: Vallon Pharmaceuticals, Inc. (now identified in the request metadata as GRI Bio, Inc.)
Form: 8-K
Report date: October 12, 2021
Primary item: Item 8.01, Other Events
Business Context and Reporting Period
The company reported that it issued a business update press release and posted an updated corporate presentation on its website on October 12, 2021. The filing does not cover a quarterly or annual reporting period.
Financial Metrics and Liquidity
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not describe quantified changes versus a prior comparable period. It only references a business update and an updated corporate presentation.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not include the substance of the business update, management guidance, outlook, risk factors, contingencies, or unusual items. Those details may be contained in Exhibits 99.1 and 99.2, which are referenced but not included in the provided filing text.
Key Facts to Verify
- Review Exhibit 99.1 for the October 12, 2021 business update and any clinical, regulatory, financing, or operational developments.
- Review Exhibit 99.2 for updated pipeline, market, financial, and outlook information.
- Confirm the registrant’s corporate identity, because the filing names Vallon Pharmaceuticals, Inc., while the request metadata identifies GRI Bio, Inc.
- Verify any financial or forward-looking statements directly against the exhibits and subsequent SEC filings.